PerpEquities

Arrowhead Pharmaceuticals, Inc. (ARWR) balance sheet

NASDAQ · Healthcare · Biotechnology · 711 employees · CEO Christopher R. Anzalone

Price
$59.90 -0.98%
Market cap
$8.46B
Enterprise value
$9.27B
Last report
Q3 '26 filed 2026-08-04
Next report
2026-11-24 EPS est. -$1.52

At the end of Q3 '26 Arrowhead Pharmaceuticals, Inc. (ARWR) held $1.6B in cash and short-term investments against $864M of debt incl. leases. Total assets $2.11B, total liabilities $1.65B, shareholders' equity $466M.

Balance sheet

Balance sheetTrendQ4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Assets
Cash & equivalents$111M$58.2M$128M$69.4M$103M$53.9M$186M$130M$227M$202M$189M$54.8M
Short-term investments$293M$162M$395M$367M$578M$499M$912M$771M$693M$715M$1.6B$1.55B
Receivables$0$0$0$0$0$2.5M$2.37M$9.7M$6.82M$219M$15.7M$8.56M
Other current assets$7.08M$7.1M$7.51M$4.18M$4.97M$5.74M$11.7M$13.2M$13.5M$38.9M$18.3M$35.5M
Current assets$420M$238M$542M$450M$695M$571M$1.14B$947M$951M$1.17B$1.84B$1.67B
Property, plant & equipment (net)$336M$378M$404M$420M$431M$432M$429M$425M$426M$422M$418M$429M
Long-term investments$0$0$0$0$0$0$0$0$0$0$4.7M$0
Intangible assets$10.3M$9.84M$9.41M$8.99M$8.56M$8.14M$7.71M$7.29M$6.86M$6.44M$6.01M$5.59M
Other non-current assets$210K$232K$210K$4.46M$4.48M$3.08M$1.31M$1.35M$1.39M$1.41M$187K$6.05M
Non-current assets$346M$388M$414M$434M$444M$443M$438M$434M$435M$430M$429M$441M
Total assets$766M$626M$955M$884M$1.14B$1.01B$1.57B$1.38B$1.39B$1.6B$2.27B$2.11B
Liabilities
Accounts payable$35.9M$4.46M$8.52M$26.6M$11.4M$14.5M$9.98M$33.1M$17.7M$32.9M$30.7M$27.8M
Accrued expenses$18M$8.78M$13.7M$15.8M$22M$11.3M$16.6M$19.3M$117M$144M$20.4M$110M
Short-term debt$10.6M$3.42M$5.29M$6.05M$6.34M$8.19M$71.8M$47M$40M$40M$47.8M$40M
Deferred revenue$866K$0$0$0$0$0$43.3M$23M$2.4M$112M$109M$94.6M
Other current liabilities$40.2M$47.1M$37.6M$48.3M$63.4M$59.8M$78.9M$72.2M$10.8M$10.7M$87.8M$11.3M
Current liabilities$105M$63.7M$65.2M$96.7M$103M$93.8M$221M$195M$195M$347M$295M$283M
Long-term debt$268M$274M$281M$336M$735M$755M$561M$561M$215M$163M$1.23B$824M
Lease obligations (non-current)$105M$115M$114M$112M$111M$109M$108M$106M$104M$102M$100M$0
Deferred revenue (non-current)$0$0$0$0$0$0$0$0$0$53.8M$48.6M$31.7M
Other non-current liabilities$0$0$0$0$0$0$0$0$367M$375M$0$507M
Non-current liabilities$373M$389M$395M$448M$846M$864M$669M$666M$686M$694M$1.37B$1.36B
Total liabilities$478M$453M$460M$545M$949M$958M$889M$861M$882M$1.04B$1.67B$1.65B
Equity
Common stock & paid-in capital$200K$200K$217K$217K$217K$218K$230K$230K$231K$233K$236K$237K
Retained earnings-$1.03B-$1.16B-$1.28B-$1.45B-$1.63B-$1.8B-$1.43B-$1.6B-$1.63B-$1.6B-$1.73B-$1.92B
Accumulated other comprehensive income-$3.22M-$1.26M-$1.1M-$987K$4.75M$4.14M$4.39M$5.36M$6.44M$6.7M$742K-$1.23M
Shareholders' equity$271M$160M$484M$331M$185M$52.6M$683M$522M$466M$568M$614M$466M
Debt
Total debt (incl. leases)$383M$392M$400M$454M$852M$872M$741M$713M$366M$313M$1.37B$864M
Net debt (debt - cash)$273M$334M$272M$385M$749M$818M$555M$583M$140M$111M$1.18B$809M

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.

Cash, investments and debt

quarter ends

The other statements

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-Q 2025-12-31, 10-K 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-Q 2024-12-31, 10-K 2024-09-30, 10-Q 2024-06-30

Data as of 2026-11-02